Joel Gelernter1, Henry R Kranzler2, Richard Sherva3, Ryan Koesterer4, Laura Almasy5, Hongyu Zhao6, Lindsay A Farrer7. 1. Department of Psychiatry, Division of Human Genetics, Departments of Genetics and Neurobiology, Yale University School of Medicine, VA Connecticut Healthcare Center, West Haven. Electronic address: joel.gelernter@yale.edu. 2. Philadelphia VA Medical Center, Philadelphia, Pennsylvania. 3. Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts. 4. University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 5. Department of Genetics, Texas Biomedical Research Institute, San Antonio, Texas. 6. Departments Biostatistics and Genetics, Yale School of Public Health, Yale University, New Haven, CT. 7. Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts; Departments of Neurology, Ophthalmology, Genetics and Genomics, Epidemiology and Biostatistics, Boston University Schools of Medicine and Public Health, Boston, Massachusetts.
Abstract
BACKGROUND: We report a genome-wide association study (GWAS) of two populations, African-American and European-American (AA, EA) for opioid dependence (OD) in three sets of subjects, to identify pathways, genes, and alleles important in OD risk. METHODS: The design employed three phases (on the basis of separate sample collections). Phase 1 included our discovery GWAS dataset consisting of 5697 subjects (58% AA) diagnosed with opioid and/or other substance dependence and control subjects. Subjects were genotyped with the Illumina OmniQuad microarray, yielding 890,000 single nucleotide polymorphisms (SNPs) suitable for analysis. Additional genotypes were imputed with the 1000 Genomes reference panel. Top-ranked findings were further evaluated in Phase 2 by incorporating information from the publicly available Study of Addiction: Genetics and Environment dataset, with GWAS data from 4063 subjects (32% AA). In Phase 3, the most significant SNPs from Phase 2 were genotyped in 2549 independent subjects (32% AA). Analyses were performed with case-control and ordinal trait designs. RESULTS: Most significant results emerged from the AA subgroup. Genome-wide-significant associations (p < 5.0 × 10(-8)) were observed with SNPs from multiple loci-KCNG2*rs62103177 was most significant after combining results from datasets in every phase of the study. The most compelling results were obtained with genes involved in potassium signaling pathways (e.g., KCNC1 and KCNG2). Pathway analysis also implicated genes involved in calcium signaling and long-term potentiation. CONCLUSIONS: This is the first study to identify risk variants for OD with GWAS. Our results strongly implicate risk pathways and provide insights into novel therapeutic and prevention strategies and might biologically bridge OD and other non-substance dependence psychiatric traits where similar pathways have been implicated.
BACKGROUND: We report a genome-wide association study (GWAS) of two populations, African-American and European-American (AA, EA) for opioid dependence (OD) in three sets of subjects, to identify pathways, genes, and alleles important in OD risk. METHODS: The design employed three phases (on the basis of separate sample collections). Phase 1 included our discovery GWAS dataset consisting of 5697 subjects (58% AA) diagnosed with opioid and/or other substance dependence and control subjects. Subjects were genotyped with the Illumina OmniQuad microarray, yielding 890,000 single nucleotide polymorphisms (SNPs) suitable for analysis. Additional genotypes were imputed with the 1000 Genomes reference panel. Top-ranked findings were further evaluated in Phase 2 by incorporating information from the publicly available Study of Addiction: Genetics and Environment dataset, with GWAS data from 4063 subjects (32% AA). In Phase 3, the most significant SNPs from Phase 2 were genotyped in 2549 independent subjects (32% AA). Analyses were performed with case-control and ordinal trait designs. RESULTS: Most significant results emerged from the AA subgroup. Genome-wide-significant associations (p < 5.0 × 10(-8)) were observed with SNPs from multiple loci-KCNG2*rs62103177 was most significant after combining results from datasets in every phase of the study. The most compelling results were obtained with genes involved in potassium signaling pathways (e.g., KCNC1 and KCNG2). Pathway analysis also implicated genes involved in calcium signaling and long-term potentiation. CONCLUSIONS: This is the first study to identify risk variants for OD with GWAS. Our results strongly implicate risk pathways and provide insights into novel therapeutic and prevention strategies and might biologically bridge OD and other non-substance dependence psychiatric traits where similar pathways have been implicated.
Authors: Valentina Moskvina; Nick Craddock; Peter Holmans; Michael J Owen; Michael C O'Donovan Journal: Hum Hered Date: 2006-04-06 Impact factor: 0.444
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Jessica A Filosa; Adrian D Bonev; Stephen V Straub; Andrea L Meredith; M Keith Wilkerson; Richard W Aldrich; Mark T Nelson Journal: Nat Neurosci Date: 2006-11 Impact factor: 24.884
Authors: M Nyegaard; D Demontis; L Foldager; A Hedemand; T J Flint; K M Sørensen; P S Andersen; M Nordentoft; T Werge; C B Pedersen; D M Hougaard; P B Mortensen; O Mors; A D Børglum Journal: Mol Psychiatry Date: 2010-02 Impact factor: 15.992
Authors: Joel Gelernter; Carolien Panhuysen; Roger Weiss; Kathleen Brady; Victor Hesselbrock; Bruce Rounsaville; James Poling; Marsha Wilcox; Lindsay Farrer; Henry R Kranzler Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-07-05 Impact factor: 3.568
Authors: Pingxing Xie; Henry R Kranzler; John H Krystal; Lindsay A Farrer; Hongyu Zhao; Joel Gelernter Journal: Addict Biol Date: 2013-07-16 Impact factor: 4.280
Authors: Shizhong Han; Bao-Zhu Yang; Henry R Kranzler; Xiaoming Liu; Hongyu Zhao; Lindsay A Farrer; Eric Boerwinkle; James B Potash; Joel Gelernter Journal: Am J Hum Genet Date: 2013-11-21 Impact factor: 11.025
Authors: Dawei Li; Hongyu Zhao; Henry R Kranzler; Ming D Li; Kevin P Jensen; Tetyana Zayats; Lindsay A Farrer; Joel Gelernter Journal: Neuropsychopharmacology Date: 2014-09-27 Impact factor: 7.853
Authors: Eric O Johnson; Dana B Hancock; Joshua L Levy; Nathan C Gaddis; Grier P Page; Cristie Glasheen; Nancy L Saccone; Laura J Bierut; Alex H Kral Journal: Addict Biol Date: 2015-07-23 Impact factor: 4.280
Authors: Jaime Derringer; Robin P Corley; Brett C Haberstick; Susan E Young; Brittany A Demmitt; Daniel P Howrigan; Robert M Kirkpatrick; William G Iacono; Matt McGue; Matthew C Keller; Sandra Brown; Susan Tapert; Christian J Hopfer; Michael C Stallings; Thomas J Crowley; Soo Hyun Rhee; Ken Krauter; John K Hewitt; Matthew B McQueen Journal: Behav Genet Date: 2015-01-31 Impact factor: 2.805
Authors: Jin Lu; Jiangwen Sun; Xinyu Wang; Henry R Kranzler; Joel Gelernter; Jinbo Bi Journal: Proceedings (IEEE Int Conf Bioinformatics Biomed) Date: 2017-12-18